Subgroup analysis of ORR and PFS of the SEQTOR study (GETNE 1206) – Everolimus followed by Streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs

#3838

Introduction: Previous global results of ORR and PFS1 have been presented. The best treatment (Tx) sequence between STZ-5FU and everolimus (EVE) in patients (pts) with advanced and progressive panNETs is not yet well established.

Aim(s): To assess the efficacy of STZ-5FU versus EVE (ORR and PFS1) according to clinically relevant variables.

Materials and methods: Pts with advanced WHO grade (G)1/2 panNETs, ECOG 0-2, were randomized 1:1 to EVE 10 mg/day followed by STZ-5FU upon progression (arm A), or the reverse sequence (arm B). The primary endpoint was the progression-free survival rate to 1st Tx (PFS1) at 12 months (m). Secondary endpoints included objective response rate (ORR). PFS1 and ORR were stratified according to age, gender, ECOG, tumor grade, tumor burden and previous treatments.

Conference:

Presenting Author: Salazar R

Authors: Capdevila J, Tafuto S, Krogh M, Teulé A, Garcia-Carbonero R,

Keywords: panNET, everolimus, STZ-5FU,